MEIRAGTX HOLDINGS PLC (MGTX)
Health Care · genetic medicine / gene therapy · NASDAQ
MeiraGTx is a vertically integrated genetic medicine company developing a pipeline of gene therapies and a unique riboswitch platform for dose-responsive, oral-small-molecule control of gene expression.
What MEIRAGTX HOLDINGS PLC does
MeiraGTx is a clinical-stage genetic medicines company focused on developing therapies for inherited and common diseases using a proprietary, vertically integrated platform. Its technology includes engineered viral vectors for localized gene delivery and a novel riboswitch gene regulation system that enables precise, oral-small-molecule control of in vivo gene expression. The company maintains end-to-end in-house manufacturing capabilities, including GMP-licensed viral vector and quality control facilities, to support its clinical pipeline in ophthalmology, neurodegenerative conditions, and salivary gland disorders.
Themes: gene therapy, in vivo gene regulation, metabolic disease / GLP-1, oncology / CAR-T, manufacturing infrastructure
Fundamentals
- Price$9.97 as of 2026-10-20 close
- Market cap$958M as of 2026-08-11 (share count; price 2026-10-20)
- 1-year return+21.0% 2025-10-20 close $8.24 → 2026-10-20 close $9.97
- P/E11.46 as of 2026-10-20
- Net margin-140.3% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing reports debt under a line we do not read, so a total would be understated.
- Revenue growth (YoY)+144.6% FY2025, SEC XBRL
- Revenue CAGR (3y)+141.0% SEC XBRL
- Beta1.17 as of 2026-09-03
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How MGTX compares in its sector
- price-to-earnings ratiobottom 25% 181 covered Health Care peers, as of 2026-10-20
- net profit marginbottom 25% 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $321M | $244M | $161M | $1.71 | -$39M† | $332000† |
| Q1 FY2026 2026-03-31 | $293000 | -$41M | -$46M | -$0.57 | $18M | $2M |
| Q4 FY2025 2025-12-31 | $75M† | $26M† | $15M† | $0.19† | $47M† | $272000† |
| Q3 FY2025 2025-09-30 | $410000 | -$46M | -$51M | -$0.62 | -$12M† | $610000† |
| Q2 FY2025 2025-06-30 | $4M | -$45M | -$39M | -$0.48 | -$44M† | $1M† |
| Q1 FY2025 2025-03-31 | $2M | -$42M | -$40M | -$0.51 | -$37M | $2M |
| Q4 FY2024 2024-12-31 | $21M† | -$31M† | -$39M† | -$0.50† | -$23M† | $1M† |
| Q3 FY2024 2024-09-30 | $11M | -$40M | -$39M | -$0.55 | -$25M† | $730000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$143M
- Total debtnot shown the filing reports its long-term debt in a form we do not read yet
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How MEIRAGTX HOLDINGS PLC looks technically
MEIRAGTX HOLDINGS PLC (MGTX) is trading 2.1% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 125 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 37, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 39, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 3 trading days ago. It is 35.0% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 2.1% below its 200-day average, the long-term trend line — a long-term downtrend | -2.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $12.37 | $12.37 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $10.19 | $10.19 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 56 calendar days ago — the swings before that are what the structure reading is measured on | 56 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 15.31. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 125 trading days ago — a "golden cross", a bullish long-term signal | 125 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 37, with sellers in control | 36.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 39, neither overbought (above 70) nor oversold (below 30) | 38.6 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($9.24 to $11.36) — its "stochastic" reading is 34 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 34.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 36 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $15.35 | $15.35 |
|---|---|---|
| From the 52-week high | it is 35.0% below its 52-week high (its highest price of the past year) | -35.0% |
| Above the 52-week low | it is 50.6% above its 52-week low (its lowest price of the past year) | +50.6% |
| Below the 52-week high | it is 35.0% below its highest point of the past year | 35.0% |
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $30.23 (set on 2019-07-09) | $30.23 |
| Given back of the 52-week move | over the past year its closes ranged ($6.99 to $14.97), and it has given back close to two thirds of its rise from last year’s low — 63% of it. Chart-watchers call 61.8%-65% given back the "golden pocket", and this is inside it — for this company that is $9.78 to $10.04. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 62.7% |
| From the all-time high | it is 67.0% below its all-time high | -67.0% |
| Nearest price level | it is trading 4.7% above a support level at $9.50 — a price it turned at twice since 2025-10-28, most recently on 2025-12-12. Since 2024-10-21 it has 13 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -4.7% |
| All-time low | its lowest closing price on record is $3.49 (set on 2023-10-25) | $3.49 |
| Above the all-time low | it is 185.7% above its all-time low | +185.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 42nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.5815 between its high and its low — about 5.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.5815 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $9.23 and $11.80 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $9.23 – $10.51 – $11.80 |
| Typical daily range (% of price) | its price moves about 5.8% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.8% |
| Stretch from the 200-day average | it is trading 0.4 daily ranges below its 200-day average price (2.1% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.4 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.76× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
3
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bullish engulfing | today it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | today |
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-20 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Open gap | it gapped 2.2% above the previous close 1 session ago and has not traded back through the level it left behind at 9.28 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.2% |
| Gap filled | a 3.3% gap up opened on 2026-10-01 has been "filled" 13 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 13 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +7.44% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 25.7 percentage points (the stock lost 24.8% while the market gained 1.0%) | -25.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 22.0 percentage points (the stock lost 18.3% while the market gained 3.6%) | -22.0% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 13.8 percentage points (the stock lost 5.3% while the market gained 8.5%) | -13.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 6.4 percentage points (the stock gained 21.0% while the market gained 14.6%) | +6.4% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 25% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 4.5% of the share price. | -25.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 7% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $10.73 — a volume-weighted average of daily closes over 196 sessions, not a true tick-by-tick VWAP. | -7.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 18% below the average price paid since it last reported on 2026-08-13 (its 10-Q), so the typical buyer over that stretch is under water. That average is $12.18 — a volume-weighted average of daily closes over 48 sessions, not a true tick-by-tick VWAP. | -18.2% |
Double top, bearish — broke down · entry $11.62 · 74 sessions in
Price levels it has turned at before
MGTX last closed at $9.97 on 2026-10-20. Since 2024-10-21 it has turned at 13 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $9.50 | Support | 4.7% below the last close | turned there twice · 2025-10-28 to 2025-12-12 |
| $8.95 | Support | 10.3% below the last close | turned there four times · 2025-07-15 to 2026-06-11 |
| $8.72 | Support | 12.6% below the last close | turned there five times · 2025-03-14 to 2026-04-29 |
| $15.33 | Resistance | 53.8% above the last close | turned there twice · 2026-07-07 to 2026-08-25 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $15.31.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 35 trading days, since 2026-09-01.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · lagging the market · Printed a bullish engulfing pair | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$27.75 range $16.00 – $50.00; median $23.50
Analyst estimates, as of 2026-10-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for MGTX
- Consensus EPS estimate-$0.4733 next reporting period, as of 2026-10-17
- Estimate change, 30 days-$0.01833 from -$0.455, on 2026-09-12, 35-day window
- Readings revised upward0% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of operating losses and dependence on continued capital raising or strategic collaborations to fund operations.","Risks inherent in clinical-stage development, including the potential for regulatory failure or lack of clinical efficacy.","Concentration risk associated with relying on strategic collaborations with major pharmaceutical partners."]
What changed in the latest 10-Q
AI-assisted comparison of MGTX's 10-Q filed 2026-05-14 against the prior one filed 2025-11-13.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-14) adds: reference to Form 10-K for year ended December 31, 2025 (versus 2024 in older filing)
- Newer filing adds: description of 'four late-stage clinical programs' with explicit mention of programs 'in the eye, Parkinson's disease and radiation-induced xerostomia'
- Newer filing adds: specific reference to 'GMP Quality Control facility with clinical and commercial licensure'
- Newer filing adds: detailed description of 'proprietary manufacturing platform process over 9 years based on more than 20 different viral vectors'
- Newer filing adds: expanded riboswitch platform focus including 'CAR-T for liquid and solid tumors and autoimmune diseases, and additionally, PNS targets addressing long-term intractable pain'
- Newer filing adds: reference to Framework Agreements dated March 9, 2025 with Hologen Limited and affiliates
- Newer filing adds: reference to Strategic Collaboration and License Agreement dated November 7, 2025 with Eli Lilly and Company (Lilly Collaboration Agreement)
- Newer filing adds: updated cumulative gross proceeds through March 31, 2026 of approximately $651.3 million from equity sales, and total of $435.0 million from collaboration, license, framework and asset purchase agreements
- Newer filing adds: cash position of $73.8 million as of March 31, 2026 and $3.3 million receivable from Janssen for PPQ and transition services
- Newer filing adds: net losses for three-month period ended March 31, 2026 of $46.3 million (versus March 31, 2025 of $40.0 million)
- Newer filing adds: accumulated deficit of $862.5 million as of March 31, 2026
- Newer filing adds: operating expenses of $41.1 million for three-month period ended March 31, 2026 (versus $43.5 million for comparable 2025 period)
- Newer filing adds: expectation that increases relating to AAV-GAD funding will be offset by Hologen strategic collaboration funding
- Newer filing adds: reference to costs for AAV-AIPL1 that 'can be offset by the funding in connection with the Lilly Collaboration Agreement'
- Removed:
- Older filing (2025-11-13) describes pipeline as 'late-stage clinical programs, including Parkinson's disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy' - newer filing removes specific mention of 'AIPL1-associated retinal dystrophy' from this introductory sentence
- Older filing references 'Johnson & Johnson Innovative Medicine (formerly known as Janssen Pharmaceuticals, Inc.)' - newer filing uses simplified reference to 'Janssen Pharmaceuticals, Inc.' or 'Janssen'
- Older filing references 'Collaboration Agreement' and 'Asset Purchase Agreement' - newer filing adds specific formal names 'Janssen Collaboration Agreement' and 'Original Asset Purchase Agreement'
- Older filing describes sale of UCLB RPGR License Agreement to Johnson & Johnson Innovative Medicine - newer filing simplifies language to direct asset sale description
- Older filing references cumulative gross proceeds through September 30, 2025 of $632.2 million from equity and $130.0 million and $125.0 million from specific agreements - these figures are replaced with updated March 31, 2026 figures
- Older filing reports cash position of $17.1 million as of September 30, 2025 - replaced with $73.8 million as of March 31, 2026
- Older filing reports accumulated deficit of $831.3 million as of September 30, 2025 - replaced with $862.5 million as of March 31, 2026
- Older filing references net losses for nine-month periods - newer filing only reports three-month period data
- Older filing mentions costs for 'xerostomia associated with Sjogren's syndrome' - newer filing removes Sjogren's syndrome reference
- Older filing references 'costs associated with the delivery of services under the Asset Purchase Agreement and related agreements' - newer filing removes this language
- Reworded:
- Older: 'late-stage clinical programs' versus Newer: 'four late-stage clinical programs' - adds quantification of programs
- Older: 'targeted local delivery' versus Newer: 'local delivery of small doses' - minor wording shift
- Older: 'Our core capabilities in viral vector and capsid optimization' versus Newer: 'We use our innovative technology in optimization of capsids, promoters, and novel translational control elements' - expanded technical description
- Older: 'bespoke synthetic riboswitch technology invented in-house' versus Newer: 'novel technology for in vivo delivery' and 'transformative riboswitch gene regulation technology' - reframing of technology description
- Older: 'allows for the precise, dose-responsive control of any transgene under the control of oral small molecules' versus Newer: 'allows precise, dose-responsive control of gene expression by oral small molecules' - simplified phrasing
- Older: 'in vivo delivery of biologic therapeutics such as the metabolic peptides' versus Newer: 'regulated in vivo delivery of metabolic peptides' - adds 'regulated' descriptor
- Older: 'cell therapy for oncology and autoimmune diseases, and long-term intractable pain' versus Newer: 'cell therapy, CAR-T for liquid and solid tumors and autoimmune diseases, and additionally, PNS targets addressing long-term intractable pain' - more specific terminology
- Older: 'We have developed unique comprehensive technology capabilities' versus Newer: 'We have developed the technology' - simplification
- Older: 'Company' versus Newer: 'company' - capitalization change in one instance
- Older: references 'upfront and milestone payments' versus Newer: specifies 'upfront and milestone payments in connection with' for clarity
- Older: 'process performance qualification' abbreviated as 'PPQ' - Newer maintains same abbreviation but both texts use it
- Notes:
- Older filing text appears truncated at end of visible section; newer filing also appears truncated mid-sentence
- Comparison limited to provided excerpts; full MD&A sections may contain additional changes not visible in truncated text
- Financial figures represent different reporting periods (March 31, 2026 versus September 30, 2025), making period-over-period comparisons not directly comparable
- Collaboration agreement entity naming conventions changed between filings (Janssen vs. Johnson & Johnson Innovative Medicine terminology)
Risk Factors
- Added:
- Newer filing (2026-05-14) adds specific mention of costs related to long-term follow up study for Phase 3 LUMEOS clinical trial of bota-vec for XLRP treatment
- Newer filing (2026-05-14) adds explicit statement that Hologen funding is 'part of the strategic collaboration we entered into with them' (versus older filing's 'anticipated closing')
- Newer filing (2026-05-14) specifies 'increasing research, preclinical and clinical activities for our riboswitch platform' separately from AAV-GAD activities
- Removed:
- Older filing (2025-11-13) contained a separate risk factor section titled 'There is no guarantee that we will receive in a timely fashion or at all the additional milestone payments contemplated under the Asset Purchase Agreement or the revenues associated with our manufacture of the commercial supply of the RPGR Product under the Supply Agreement' with details about the December 20, 2023 Johnson & Johnson transaction—this section is not present in newer filing (2026-05-14)
- Reworded:
- Net loss figures changed from 'nine months ended September 30, 2025, and 2024' ($129.3 million and $108.4 million) in older filing to 'three months ended March 31, 2026, and 2025' ($46.3 million and $40.0 million) in newer filing
- Accumulated deficit changed from '$831.3 million' as of September 30, 2025 in older filing to '$862.5 million' as of March 31, 2026 in newer filing
- Hologen funding language changed from 'although certain of these increases are expected to be offset by the funding provided by Hologen after the anticipated closing of the strategic collaboration we entered into with them' to 'although certain of these increases are expected to be offset by the funding provided by Hologen as part of the strategic collaboration we entered into with them'
- Older filing references 'EMA,' (with comma after parenthesis) while newer filing references 'EMA' (without comma)
- Notes:
- The newer filing appears truncated at the end ('Our failure to raise capital as and when needed would have a negative effect on our financial condition and our ability to pursue our business s'), suggesting the full text may not have been provided for comparison
- The older filing text also appears truncated at the end regarding the Johnson & Johnson Asset Purchase Agreement details, limiting full assessment of removals
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 3 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 30 days · read to 2026-10-160 buys · 2 sells ($851492) — 2 selling insiders
- Last 90 days · read to 2026-10-160 buys · 3 sells ($2M) — 3 selling insiders
- Last 180 days · read to 2026-10-160 buys · 7 sells ($3M) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-20. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about MGTX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
MGTX had 5,996,760 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
MGTX had 6.24% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.04 days to cover at the same settlement.
- Reported short interest (shares) 5,996,760
- Short interest (% of shares outstanding) 6.24%
- Prior settlement (shares) 4,011,818
- Reported change 49.48%
- Days to cover (reported) 5.04
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Spark Therapeutics (Roche)
- REGENXBIO (RGNX)
- Bluebird Bio (BLUE)
- Editas Medicine (EDIT)
- CRISPR Therapeutics (CRSP)
- Beam Therapeutics (BEAM)
- UniQure (QURE)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare MGTX vs…
MEIRAGTX HOLDINGS PLC is found in…
Frequently asked questions
What does MEIRAGTX HOLDINGS PLC (MGTX) do?
MeiraGTx is a clinical-stage genetic medicines company focused on developing therapies for inherited and common diseases using a proprietary, vertically integrated platform. Its technology includes engineered viral vectors for localized gene delivery and a novel riboswitch gene regulation system that enables precise, oral-small-molecule control of in vivo gene expression.
What sector is MEIRAGTX HOLDINGS PLC (MGTX) in?
MEIRAGTX HOLDINGS PLC (MGTX) is classified in the Health Care sector. Its industry is genetic medicine / gene therapy. It trades on NASDAQ.
Who are MEIRAGTX HOLDINGS PLC's (MGTX) competitors?
Notable peers of MEIRAGTX HOLDINGS PLC (MGTX) include Spark Therapeutics (Roche), REGENXBIO, Bluebird Bio, Editas Medicine and CRISPR Therapeutics. This peer set is informational only — not financial advice.
Is MEIRAGTX HOLDINGS PLC (MGTX) overbought or oversold right now?
MEIRAGTX HOLDINGS PLC (MGTX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 39, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on MGTX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.